Farxiga Vs. Invokana: Drug Comparison

Farxiga^® (dapagliflozin) is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor used to treat type 2 diabetes, heart failure, and chronic kidney disease. It lowers blood sugar by promoting glucose excretion through the urine. Farxiga is indicated for reducing the risk of estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, cardiovascular death, and heart failure hospitalization in adults with chronic kidney disease. Additionally, it reduces the risk of cardiovascular death, heart failure hospitalization, and urgent heart failure visits in adults with heart failure. It decreases heart failure hospitalization risk in adults with type 2 diabetes and cardiovascular disease or risk factors. Farxiga also aids in improving glycemic control alongside diet and exercise in adults and children aged 10 and older with type 2 diabetes. Common side effects include urinary and genital infections, and it may cause rare but serious conditions like ketoacidosis and dehydration.

Invokana^® (canagliflozin) is an oral medication used to manage type 2 diabetes by inhibiting sodium-glucose co-transporter 2 (SGLT2) in the kidneys, which helps lower blood sugar by increasing glucose excretion in the urine. Its FDA-approved indications include improving blood sugar control in adults with type 2 diabetes and reducing the risk of cardiovascular events and kidney complications in certain patients with type 2 diabetes and cardiovascular disease. Off-label uses may include treating heart failure and managing chronic kidney disease in patients without diabetes. Invokana is available in tablet form, taken once daily. Common side effects include urinary tract infections and increased urination. There is an increased risk of lower limb amputations, particularly in patients with existing cardiovascular issues or peripheral vascular disease.

Sodium-glucose cotransporter 2 (SGLT2) inhibitor

Sodium-glucose co-transporter 2 (SGLT2) inhibitor

Farxiga (dapagliflozin) is indicated:

• To reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression

• To reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure

• To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors

• As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus

Invokana (canagliflozin) is indicated:

• As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

• To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease

• To reduce the risk of end-stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria

• Typically taken orally once daily

• Comes in 5 mg and 10 mg tablets

• Typically taken orally once daily

• Comes in 100 mg and 300 mg tablets

Most common adverse reactions (5% or greater incidence) were:

• Female genital fungal infections

• Inflammation of the nasal cavities and back of the throat

• Urinary tract infections

Most common adverse reactions (5% or greater incidence):

• Female genital fungal infections

• Urinary tract infection

• Increased urination

• History of serious hypersensitivity reaction to dapagliflozin or any of the excipients in Farxiga

• See the Full Prescribing Information for information on drug interactions and interference of Farxiga with laboratory tests

• Serious hypersensitivity reaction to Invokana

• Drug interactions: See full prescribing information for information on drug interactions and interference of Invokana with laboratory tests

• Diabetic ketoacidosis in patients with type 1 diabetes mellitus and other ketoacidosis

• Volume depletion

• Urosepsis and pyelonephritis

• Low blood sugar

• Necrotizing fasciitis of the perineum (Fournier’s gangrene)

• Genital fungal infections

• Pregnancy: Potential risk to a fetus especially during the second and third trimesters

• Lactation: Not recommended when breastfeeding

• Diabetic ketoacidosis in patients with type 1 diabetes mellitus and other ketoacidosis

• Lower limb amputation

• Volume depletion: May result in acute kidney injury

• Urosepsis and pyelonephritis

• Low blood sugar with concomitant use with insulin or insulin secretagogues

• Necrotizing fasciitis of the perineum (Fournier's gangrene)

• Genital fungal infections

• Hypersensitivity reactions

• Bone fracture

• Pregnancy: Advise females of the potential risk to a fetus especially during the second and third trimesters

• Breastfeeding: Not recommended when breastfeeding

*This information is from the label for brand name Farxiga^®. See the Full Prescribing Information for more complete information.

*This information is from the label for brand name Invokana^®. See the Full Prescribing Information for more complete information.